These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 19384186

  • 1. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
    Oberbauer R.
    Transplantation; 2009 Apr 27; 87(8 Suppl):S7-10. PubMed ID: 19384186
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 4. Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study.
    Cardinal H, Froidure A, Dandavino R, Daloze P, Hébert MJ, Colette S, Boucher A.
    Transplant Proc; 2009 Oct 27; 41(8):3308-10. PubMed ID: 19857737
    [Abstract] [Full Text] [Related]

  • 5. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED.
    J Heart Lung Transplant; 2009 Jun 27; 28(6):564-71. PubMed ID: 19481016
    [Abstract] [Full Text] [Related]

  • 9. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.
    Bäckman L, Reisaeter AV, Wramner L, Ericzon BG, Salmela K, Brattström C.
    Clin Transplant; 2006 Jun 27; 20(3):336-9. PubMed ID: 16824151
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
    Stephany BR, Augustine JJ, Krishnamurthi V, Goldfarb DA, Flechner SM, Braun WE, Hricik DE, Dennis VW, Poggio ED.
    Transplantation; 2006 Aug 15; 82(3):368-74. PubMed ID: 16906035
    [Abstract] [Full Text] [Related]

  • 12. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 13. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
    Demirjian S, Stephany B, Abu Romeh IS, Boumitri M, Yamani MH, Poggio ED.
    Clin Transplant; 2009 Nov 15; 23(3):351-60. PubMed ID: 19208105
    [Abstract] [Full Text] [Related]

  • 14. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B, Fischereder M, Jauch KW, Graeb C, Hoffmann U, Böger CA, Banas B, Obed A, Schlitt HJ, Krämer BK.
    Transplant Proc; 2007 Mar 15; 39(2):518-21. PubMed ID: 17362772
    [Abstract] [Full Text] [Related]

  • 15. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J.
    Transplant Proc; 2009 Dec 15; 41(10):4138-46. PubMed ID: 20005355
    [Abstract] [Full Text] [Related]

  • 16. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients.
    Rogers CC, Johnson SR, Mandelbrot DA, Pavlakis M, Horwedel T, Karp SJ, Egbuna O, Rodrigue JR, Chudzinski RE, Goldfarb-Rumyantzev AS, Hanto DW, Curry MP.
    Clin Transplant; 2009 Dec 15; 23(6):887-96. PubMed ID: 19681971
    [Abstract] [Full Text] [Related]

  • 17. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
    Peddi VR, Jensik S, Pescovitz M, Pirsch J, Adler SH, Thistlethwaite JR, Vincenti F, Cohen DJ.
    Clin Transplant; 2005 Feb 15; 19(1):130-6. PubMed ID: 15659146
    [Abstract] [Full Text] [Related]

  • 18. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E, Cerezo I, Macias R, Villa J, Martinez C, Cubero J, Martinez R, Ferreira F, García C.
    Transplant Proc; 2011 Feb 15; 43(6):2187-90. PubMed ID: 21839229
    [Abstract] [Full Text] [Related]

  • 19. New approaches to de novo immunosuppression and steroid elimination.
    Lebranchu Y.
    Transplant Proc; 2009 Feb 15; 41(6 Suppl):S39-41. PubMed ID: 19651295
    [Abstract] [Full Text] [Related]

  • 20. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C.
    Pediatr Transplant; 2006 Jun 15; 10(4):474-8. PubMed ID: 16712606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.